All editorial reviews, updates, and methodology refinements in reverse chronological order. Maintained by the GLPOneMedical advisory board.
GLPOneMedical's editorial archive lists every dated review update, methodology refinement, and provider re-scoring event. Maintained as part of transparency commitment.
July 2026
- July 8, 2026 — Phase 3 expansion published. Added clinical deep-dives (10), verification guides (8), patient journey (8), cost playbooks (6), priority state depth (8), best lists (5). Total: 265+ pages.
- July 8, 2026 — UHC CV indication coverage analyzed. Added to UHC coverage page.
- July 8, 2026 — Foundayo phase 3 CV safety analysis covered. Q4 2026 launch confirmed in Foundayo page.
- July 8, 2026 — Anthem BCBS Zepbound OSA coverage in 14 states added.
- July 8, 2026 — State pharmacy board investigations covered in regulatory section.
- July 8, 2026 — ESSENCE phase 3 interim added to MASH page.
July 2026
- July 8, 2026 — CMS Medicare Part D Wegovy coverage expansion analyzed. Added to Medicare Part D page.
- July 8, 2026 — FDA action on unapproved salt-form APIs analyzed in detail. See July 2026 FDA action page.
Methodology refinements
- July 2026 — Six-criterion rubric committed and published. See methodology.
- July 2026 — Provider scoring committee established. Four board-certified physicians; no provider equity or compensation.
- July 2026 — Affiliate disclosure framework published. See affiliate disclosure and COI.
Provider review history
NexLife scored 94/100 on initial review. Re-review scheduled at 90-day cadence. All 10 providers re-reviewed quarterly.
Corrections
No published corrections at this time. Corrections will be appended here with the date, original statement, and revised statement.